# Neonc Technologies Holdings, Inc.: overview

NTHI · Nasdaq · CIK 1979414 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nthi.md) · [Financials](/companies/nthi/financials.md) · [Filings](/companies/nthi/filings.md) · [Insiders](/companies/nthi/insiders.md)

Latest reported revenue: [$0](/filings/0001829126-26-008512.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 10, 2026 (XBRL us-gaap:Revenues, accession 0001829126-26-008512).

## Last eight quarters

| Line item | Unit | period not labelled (2024-09-30) | period not labelled (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [0.0 d](/filings/0001829126-25-009210.md) | [20.0 d](/filings/0001829126-26-002860.md) | [40.0](/filings/0001829126-26-005358.md) | [0.0 d](/filings/0001829126-26-008512.md) | [0.0 d](/filings/0001829126-25-009210.md) | [0.0 d](/filings/0001829126-26-002860.md) | not reported | [0.0](/filings/0001829126-26-008512.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | [(10568.7%) d](/filings/0001829126-26-002860.md) | [(79772.0%)](/filings/0001829126-26-005358.md) | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | [(11264.9%) d](/filings/0001829126-26-002860.md) | [(80835.2%)](/filings/0001829126-26-005358.md) | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.12)](/filings/0001829126-25-009210.md) | not reported | [(1.78)](/filings/0001829126-26-005358.md) | [(0.30)](/filings/0001829126-26-008512.md) | [(0.45)](/filings/0001829126-25-009210.md) | not reported | [(0.38)](/filings/0001829126-26-005358.md) | [(0.58)](/filings/0001829126-26-008512.md) |
| Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: |
| Revenue | $m | [0.1](/filings/0001829126-26-002860.md) | [0.0](/filings/0001829126-26-002860.md) |
| Gross margin | % | not reported | not reported |
| Operating margin | % | [(8605.4%)](/filings/0001829126-26-002860.md) | [(145637.5%)](/filings/0001829126-26-002860.md) |
| Net margin | % | [(14335.5%)](/filings/0001829126-26-002860.md) | [(155404.4%)](/filings/0001829126-26-002860.md) |
| Diluted EPS | $ per share | [(0.69)](/filings/0001829126-26-002860.md) | [(3.20)](/filings/0001829126-26-002860.md) |
| Free cash flow | $m | not reported | [(20.9)](/filings/0001829126-26-002860.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/nthi/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Cinctive Capital Management LP](/funds/1787258.md) | 2026-06-30 | $7.3m | 1,607,464 |  | Added +181,938 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.3m | 504,171 |  | Added +288,471 |
| [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $1.0m | 224,412 |  | Reduced −10,984 |
| [Westmount Partners, LLC](/funds/2051491.md) | 2026-06-30 | $893.2k | 197,178 |  | Added +153,858 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $814.7k | 179,850 |  | Added +24,012 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $752.8k | 166,120 |  | Added +39,267 |
| [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $414.4k | 91,480 |  | Added +35,464 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $195.6k | 43,170 |  | Unchanged |
| [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $162.5k | 35,871 |  | Added +12,600 |
| [Global Retirement Partners, LLC](/funds/1749744.md) | 2026-06-30 | $125.9k | 27,790 |  | Not compared |

## Recent filings

[All 205 filings](/companies/nthi/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-22 | 21:20 ET | [8-K](/filings/0001829126-26-011446.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001829126-26-011446 |
| 2026-10-15 | 20:30 ET | [8-K](/filings/0001829126-26-011189.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001829126-26-011189 |
| 2026-09-28 | 21:00 ET | [8-K](/filings/0001829126-26-010493.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001829126-26-010493 |
| 2026-09-21 | 20:30 ET | [8-K](/filings/0001829126-26-010282.md) | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001829126-26-010282 |
| 2026-09-17 | 10:02 ET | [8-K](/filings/0001829126-26-010156.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001829126-26-010156 |
| 2026-09-10 | 14:27 ET | [8-K](/filings/0001829126-26-009977.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001829126-26-009977 |
| 2026-08-21 | 18:58 ET | [8-K/A](/filings/0001829126-26-009220.md) | 5.02 Departure or appointment of officers or directors | 0001829126-26-009220 |
| 2026-08-20 | 13:00 ET | [8-K](/filings/0001829126-26-009103.md) | 5.07 Shareholder vote results | 0001829126-26-009103 |
| 2026-08-13 | 21:21 ET | [8-K](/filings/0001829126-26-008773.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001829126-26-008773 |
| 2026-08-12 | 12:30 ET | [8-K](/filings/0001829126-26-008654.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001829126-26-008654 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001829126-26-002860.md), filed Mar 31, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/2f75e2de-5c93-4f94-bc79-de47e6282ba1)

## About the filer

- CIK: 1979414
- Tickers: NTHI
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.